You are here

In Vitro Culture Model of the Human Blood-Brain Barrier

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA101703-01
Agency Tracking Number: CA101703
Amount: $369,087.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MATTEK CORPORATION 200 HOMER AVE
ASHLAND, MA 01721
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PATRICK HAYDEN
 (508) 881-6771
 PHAYDEN@MATTEK.COM
Business Contact
 JOHN SHEASGREEN
Phone: (508) 881-6771
Email: JSHEASGREEN@MATTEK.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant):
Solute distribution between blood and brain is strictly regulated by the blood-brain barrier (BBB) at brain capillary endothelial cells. While the BBB performs an important function in keeping unnecessary or harmful molecules from the brain, it poses a challenging problem in delivering therapeutics, including anticancer, antibiotic or antipsychotic drugs into the brain. Conversely, preventing potentially damaging molecules from overcoming the BBB is also an increasing problem, especially when combinations of xenobiotics are encountered. Medical and pharmaceutical scientists therefore have a growing need for rapid, reliable in vitro models of the human BBB for preclinical safety and efficacy screening. To fulfill this unmet need, an in vitro BBB model based on human endothelial cells will be developed. Human endothelial cells will be co-cultured with human astrocytes on a microporous membrane coated with extracellular matrix material in defined serum-free medium to produce a tight monolayer of endothelial cells possessing BBB properties. The model will be characterized in Phase I with respect to important attributes of the BBB function including formation of functional tight junctions and expression of functional efflux transporters. Further characterization and validation will proceed during Phase Il, and the model will be used to study strategies for modulation of BBB function.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government